Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study enrolled 728 PAH patients on oral background therapies who are randomly receiving either ralinepag (up to 400 micrograms daily) or placebo.
The primary goal is to determine whether ralinepag delays clinical worsening events including death, unplanned hospitalization, or disease progression. Results are expected in the first half of 2026, with data collection continuing through the end of this year. Participants completing the Phase 3 trial will be able to continue into a long-term extension study.
Read more at this link on Pulmonary Hypertension News